# US 10,246,488 B2 · Use of inhibitory peptides for the treatment of inflammatory diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,246,488 B2 - Document ID: US10246488B2 - Status: Granted - Kind: B2 - Application number: 15/623,433 - Filed: 2017-06-15 - Published: 2017-10-05 - Granted: 2019-04-02 - Earliest claimed: 2013-04-25 - Assignees: Yeda Research and Development Co. Ltd. - Applicants: Yeda Research and Development Co. Ltd. - Inventors: Rony Seger; Eldar Zehorai - Web page: https://patentgrep.com/patent/US10246488B2 ## CPC - C07K 7/06: having 5 to 11 amino acids - A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine} - A61P 37/00: Drugs for immunological or allergic disorders - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids. ## Claims ### Claim 1 An isolated peptide comprising an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1(PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids. ### Claim 2 (depends on 1) The isolated peptide of claim 1, being capable of preventing P38α nuclear translocation, the peptide being no longer than 20 amino acids. ### Claim 3 (depends on 1) The isolated peptide of claim 1, comprising the sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 8. ### Claim 4 (depends on 1) The isolated peptide of claim 1, wherein a heterologous substance is linked to said amino acid sequence via a linker. ### Claim 5 (depends on 1) The isolated peptide of claim 1, comprising the amino acid sequence as selected from the group consisting of SEQ ID NO: 2 (PERYQNLSPVG), SEQ ID NO: 3 (PERYQNLSPVGS), SEQ ID NO: 4 (PERYQNLSPVGSG) and SEQ ID NO: 5 (PERYQNLSPVGSGA), SEQ ID NO: 6 (KPERYQNLSPVGSGA) and SEQ ID NO: 7 (KPERYQNLSPVAAAA). ### Claim 6 (depends on 1) The isolated peptide of claim 1, being myristoylated. ### Claim 7 (depends on 1) A method of treating an inflammatory disorder or an immune disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of the isolated peptide of claim 1 into the subject, thereby treating the inflammatory disorder or immune disorder. ### Claim 8 (depends on 7) The method of claim 7, wherein the immune disorder is an autoimmune disorder. ### Claim 9 (depends on 7) The method of claim 7, wherein the inflammatory disorder is colitis. ### Claim 10 (depends on 1) A composition of matter comprising the isolated peptide of claim 1 and a heterologous substance linked to said amino acid sequence via a linker. ### Claim 11 (depends on 1) A method of targeting a substance into a nucleus of a host cell, the method comprising introducing the substance into the host cell, the substance being attached to the peptide of claim 1. ### Claim 12 (depends on 1) A method of targeting a substance into a nucleus of a host cell, the method comprising introducing the peptide of claim 1 into the host cell, said peptide being linked to an affinity moiety capable of binding the substance. ### Claim 13 (depends on 1) A pharmaceutical composition comprising as an active agent the peptide of claim 1 and a pharmaceutically acceptable carrier. ### Claim 14 (depends on 1) The isolated peptide of claim 1, being lipidated.